An initiative of the World Peptide Foundation · Every experience matters
Loading the peptide directory…
Lanreotide — Peptide Scientific Intelligence
Scientific intelligence record
Experience 2.0
Somatostatin analog
Lanreotide
Lanreotide is a synthetic cyclic octapeptide somatostatin analog with high affinity particularly for somatostatin receptor subtypes 2 and 5. Receptor activation suppresses growth-hormone secretion and multiple gastroenteropancreatic hormones and can exert antiproliferative effects in selected somatostatin-receptor-expressing neuroendocrine tumors. Depot and Autogel formulations provide prolonged exposure; approved indications and administration requirements vary by product and jurisdiction.
Record status
Traceability partial
Last meaningful update: 9/9/2026
Evidence searched through:
Not recorded
Assessment updated:
9/9/2026
Last human review:
No accountable human review represented
Governed reviewed evidence
25
Governed records, not an efficacy score or total literature count.
Evidence boundary
0 / 25
Claim-linked support versus recorded evidence.
Research gaps
1
Unresolved questions remain visible.
Human experience · separate evidence stream
No community pattern is displayed yet
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
Research chronology
2000 · study · Temporal status not established
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Clinical endocrinology
2002 · study · Temporal status not established
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
The Journal of clinical endocrinology and metabolism
2005 · study · Temporal status not established
Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.
Metabolism: clinical and experimental
2006 · study · Temporal status not established
Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
Clinical endocrinology
Connections
Follow the scientific relationships
Connections appear only when they are represented by the project’s underlying records.
Open 12 represented connections ↓Close represented connections ↑
institution
The Journal of clinical endocrinology and metabolism
represented evidence source
institution
Pituitary
represented evidence source
institution
The oncologist
represented evidence source
institution
Traceability
Follow the record back to its source
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Claim → Evidence
Incomplete
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Incomplete links: claim-to-evidence
Inspect 25 source paths ↓Close source paths ↑
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Observational archive
What contributors reported
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Reviewed jurisdictional records
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Read the scientific record with its boundaries intact
The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Lanreotide evidence · ranking key
How evidence is ranked
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
A
Practice-defining evidence
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
D
Signal-generating evidence
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
Tier and confidence answer different questions
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
peptide explorer
Structural visualization and provenance
Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.
Duplicate-safe scientific sources under accountable human review. Identified or pending records do not contribute as approved evidence.
0
Insufficient
WPF-EMM-1.0
Identified sources
6
Governed reviewed
0
Evidence approved for publication
0
Audit view
Evidence integrity map
Human and preclinical evidence remain separate. Source identity, claim-to-source traceability, review dates, conflicts, limitations, and unknowns stay visible rather than being collapsed into one score.
4 unresolved signals
Human evidence
0
Preclinical evidence
0
Human experience
Below display gate
Observations never become clinical evidence.
• Interpretation depends on tumor site, grade, receptor expression, prior therapy, secretory status, acromegaly control criteria, formulation, injection technique, and follow-up. Gallbladder effects, glucose dysregulation, bradycardia, thyroid changes, gastrointestinal effects, injection-site problems, and drug interactions require clinical context. Open-label extensions and observational cohorts are susceptible to selection and attrition; spontaneous-report databases have reporting bias and no reliable denominator. Current official labeling—not this profile—controls use and monitoring.
• The presence of published evidence does not by itself establish safety, efficacy, causation or clinical benefit.
Inspect the published evidence record25 governed records · titles, provenance, and original-source linksOpen records ↓Close records ↑
2014Phase 3 human evidence
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited.
Authors
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.
Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly.
Authors
Philippe J Caron, John S Bevan, Stephan Petersenn, Daniel Flanagan, Antoine Tabarin, Gaëtan Prévost, Pascal Maisonobe, Antoine Clermont, PRIMARYS Investigators
Source
The Journal of clinical endocrinology and metabolism
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.
To evaluate the effects of lanreotide Autogel on patient-reported outcomes and association with biochemical control, using PRIMARYS data.
Authors
Philippe J Caron, John S Bevan, Stephan Petersenn, Aude Houchard, Caroline Sert, Susan M Webb, PRIMARYS Investigators Group
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.
Somatostatin analogs are the first-line medical therapy for acromegaly, and the treatment of this disease has been simplified by the development of extended-release formulations of these analogs.
Authors
Joseph M Cendros, Concepción Peraire, Iñaki Fernández Trocóniz, Rossend Obach
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Urinary 5-hydroxyindoleacetic acid (5-HIAA) is an established biomarker in neuroendocrine tumors and carcinoid syndrome; however, its role in nonfunctional neuroendocrine tumors is not defined.
Authors
Marianne E Pavel, Alexandria T Phan, Edward M Wolin, Beloo Mirakhur, Nilani Liyanage, Susan Pitman Lowenthal, George A Fisher, Aaron I Vinik, CLARINET Study Investigators
Source
The oncologist
DOI
10.1634/theoncologist.2018-0217
PubMed
2016Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
To evaluate the efficacy and safety of lanreotide depot/autogel 120 mg for the control of carcinoid syndrome (CS) symptoms in patients with neuroendocrine tumors (NETs).
Authors
Aaron I Vinik, Edward M Wolin, Nilani Liyanage, Edda Gomez-Panzani, George A Fisher, ELECT Study Group *
Source
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
DOI
10.4158/ep151172.or
PubMed
2018Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naïve to prior somatostatin analogue treatment (de novo group).
Authors
George A Fisher, Edward M Wolin, Nilani Liyanage, Susan Pitman Lowenthal, Beloo Mirakhur, Rodney F Pommier, Montaser Shaheen, Aaron I Vinik, ELECT Study Investigators
Source
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2014Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Many patients with acromegaly do not achieve biochemical control despite receiving high doses of the first-generation somatostatin analogues octreotide or lanreotide.
Authors
Mônica R Gadelha, Marcello D Bronstein, Thierry Brue, Mihail Coculescu, Maria Fleseriu, Mirtha Guitelman, Vyacheslav Pronin, Gérald Raverot, Ilan Shimon, Kayo Kodama Lievre, Juergen Fleck, Mounir Aout
Source
The lancet. Diabetes & endocrinology
DOI
10.1016/s2213-8587(14)70169-x
PubMed
2013Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
The somatostatin analog lanreotide Autogel has proven to be efficacious for treating acromegaly in international studies and in clinical practices around the world.
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
Lanreotide autogel is a somatostatin analog (SSA) approved for the treatment of acromegaly in 73 countries worldwide; however, it is not yet approved in China.
Authors
Zhenmei An, Ting Lei, Lian Duan, Pei Hu, Zhongping Gou, Lihui Zhang, Lucie Durand-Gasselin, Nan Wang, Yan Wang, Feng Gu, LANTERN study investigators
Source
BMC endocrine disorders
DOI
10.1186/s12902-020-0524-7
PubMed
2006Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
Depot somatostatin analogues are well accepted as either adjuvant or primary therapy for acromegaly, and their long dosage intervals facilitate adherence to treatment.
Authors
T Lucas, R Astorga, Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
The most effective option for the medical treatment of patients with acromegaly is the use of somatostatin analogues.
Authors
P Chanson, V Boerlin, C Ajzenberg, Y Bachelot, P Benito, J Bringer, P Caron, B Charbonnel, C Cortet, B Delemer, F Escobar-Jiménez, L Foubert
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.
Lanreotide is a somatostatin analogue used for the treatment of acromegaly and neuroendocrine tumours.
Authors
Iñaki F Trocóniz, Josep-María Cendrós, Concepción Peraire, Joaquim Ramis, Maria J Garrido, Paolo F Boscani, Rosendo Obach
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys and loss of renal function, eventually leading to a need for kidney replacement therapy.
Authors
Esther Meijer, Folkert W Visser, Rene M M van Aerts, Charles J Blijdorp, Niek F Casteleijn, Hedwig M A D'Agnolo, Shosha E I Dekker, Joost P H Drenth, Johan W de Fijter, Maatje D A van Gastel, Tom J Gevers, Marten A Lantinga
Source
JAMA
DOI
10.1001/jama.2018.15870
PubMed
2016Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs).
Authors
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley
Source
Endocrine-related cancer
DOI
10.1530/erc-15-0490
PubMed
26743120
2019Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
Polycystic liver disease is the most common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD).
Authors
Rene M M van Aerts, Wietske Kievit, Hedwig M A D'Agnolo, Charles J Blijdorp, Niek F Casteleijn, Shosha E I Dekker, Johan W de Fijter, Maatje van Gastel, Tom J Gevers, Liyanne F M van de Laarschot, Marten A Lantinga, Monique Losekoot
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
Therapy for polycystic liver is invasive, expensive, and has disappointing long-term results.
Authors
Loes van Keimpema, Frederik Nevens, Ragna Vanslembrouck, Martijn G H van Oijen, Aswin L Hoffmann, Helena M Dekker, Robert A de Man, Joost P H Drenth
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.
Somatostatin analogs octreotide long-acting release (octLAR) and lanreotide are equally acceptable in National Comprehensive Cancer Network guidelines for neuroendocrine tumors (NETs).
Authors
Nitya Raj, Elizabeth Cruz, Sarah O'Shaughnessy, Claudia Calderon, Joanne F Chou, Marinela Capanu, Olivia Heffernan, April DeMore, Sippy Punn, Tiffany Le, Haley Hauser, Leonard Saltz
Source
JCO oncology practice
DOI
10.1200/op.22.00055
PubMed
2002Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe.
Authors
Ph Caron, A Beckers, D R Cullen, M I Goth, B Gutt, P Laurberg, A M Pico, M Valimaki, W Zgliczynski
Source
The Journal of clinical endocrinology and metabolism
Evidence strength B · 75/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours.
Authors
Philippe Ruszniewski, Juan W Valle, Catherine Lombard-Bohas, Daniel J Cuthbertson, Petros Perros, Luboš Holubec, Gianfranco Delle Fave, Denis Smith, Patricia Niccoli, Pascal Maisonobe, Philippe Atlan, Martyn E Caplin
Source
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
DOI
10.1016/j.dld.2015.12.013
2025Observational human evidence
Evidence strength B · 75/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Safety profile of lanreotide: a retrospective post-marketing pharmacovigilance study based on the real-world data from FAERS database.
Lanreotide, a class of synthetic somatostatin analogs (SSAs), is the recommended first-line treatment for neuroendocrine tumors (NETs) and acromegaly.
Evidence strength B · 75/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.
Lanreotide and Octreotide are used to treat various endocrine and neoplastic diseases.
Evidence strength A · 86/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.
Long-acting somatostatin analogs (SSA) are widely used for the treatment of acromegaly achieving biochemical control of the disease in 50-75% of the patients.
Evidence strength B · 75/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors.
Authors
Anja Rinke, Christoph Maintz, Lothar Müller, Matthias M Weber, Harald Lahner, Marianne Pavel, Wolfgang Saeger, Aude Houchard, Hanna Ungewiss, Stephan Petersenn
Source
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
DOI
10.1055/a-1342-2755
PubMed
2017Observational human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Directness
85/100
Replication
70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Neuroendocrine tumors (NETs) are a heterogeneous group of tumors, with >50% of cases involving the gastrointestinal system or pancreas.
Authors
Michael Michael, Rocio Garcia-Carbonero, Matthias M Weber, Catherine Lombard-Bohas, Christos Toumpanakis, Rodney J Hicks
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
2009 · study · Temporal status not established
Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.
Clinical pharmacokinetics
2009 · study · Temporal status not established
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
Gastroenterology
2010 · study · Temporal status not established
Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.
Pituitary
2013 · study · Temporal status not established
Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Endocrine journal
2014 · study · Temporal status not established
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
The New England journal of medicine
2014 · study · Temporal status not established
Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.
The Journal of clinical endocrinology and metabolism
2014 · study · Temporal status not established
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
The lancet. Diabetes & endocrinology
2016 · study · Temporal status not established
Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.
Pituitary
2016 · study · Temporal status not established
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2016 · study · Temporal status not established
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
Endocrine-related cancer
2016 · study · Temporal status not established
Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
2017 · study · Temporal status not established
The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
The oncologist
2018 · study · Temporal status not established
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2018 · study · Temporal status not established
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
JAMA
2019 · study · Temporal status not established
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
The oncologist
2019 · study · Temporal status not established
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
Gastroenterology
2020 · study · Temporal status not established
Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
BMC endocrine disorders
2021 · study · Temporal status not established
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
2022 · study · Temporal status not established
A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.
JCO oncology practice
2025 · study · Temporal status not established
Safety profile of lanreotide: a retrospective post-marketing pharmacovigilance study based on the real-world data from FAERS database.
Endocrine
2025 · study · Temporal status not established
Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.
Scientific reports
2026 · regulatory · Temporal status not established
Regulatory review: approved
United States (FDA — SOMATULINE DEPOT)
2026 · regulatory · Temporal status not established
Regulatory review: approved
United States (FDA — lanreotide acetate)
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
What still needs investigation
Claim traceability
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
Researchers represented in the evidence record12 bibliographic identities · open to inspect
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
Edward M Wolin
5 represented evidence records
Years represented: 2014, 2016, 2018, 2019
Publishing organizations appearing in records: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, Endocrine-related cancer, The New England journal of medicine, The oncologist
Aaron I Vinik
3 represented evidence records
Years represented: 2016, 2018, 2019
Publishing organizations appearing in records: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, The oncologist
Alexandria T Phan
3 represented evidence records
Years represented: 2014, 2016, 2019
Publishing organizations appearing in records: Endocrine-related cancer, The New England journal of medicine, The oncologist
George A Fisher
3 represented evidence records
Years represented: 2016, 2018, 2019
Publishing organizations appearing in records: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, The oncologist
Marianne Pavel
3 represented evidence records
Years represented: 2014, 2016, 2021
Publishing organizations appearing in records: Endocrine-related cancer, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, The New England journal of medicine
Nilani Liyanage
3 represented evidence records
Years represented: 2016, 2018, 2019
Publishing organizations appearing in records: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, The oncologist
Stephan Petersenn
3 represented evidence records
Years represented: 2014, 2016, 2021
Publishing organizations appearing in records: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, Pituitary, The Journal of clinical endocrinology and metabolism
Alison Langley
2 represented evidence records
Years represented: 2014, 2016
Publishing organizations appearing in records: Endocrine-related cancer, The New England journal of medicine
Aude Houchard
2 represented evidence records
Years represented: 2016, 2021
Publishing organizations appearing in records: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, Pituitary
Beloo Mirakhur
2 represented evidence records
Years represented: 2018, 2019
Publishing organizations appearing in records: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, The oncologist
Catherine Lombard-Bohas
2 represented evidence records
Years represented: 2016, 2017
Publishing organizations appearing in records: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, The oncologist
Charles J Blijdorp
2 represented evidence records
Years represented: 2018, 2019
Publishing organizations appearing in records: Gastroenterology, JAMA
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
represented evidence source
institution
Clinical endocrinology
represented evidence source
institution
Gastroenterology
represented evidence source
institution
The New England journal of medicine
represented evidence source
institution
Metabolism: clinical and experimental
represented evidence source
institution
The lancet. Diabetes & endocrinology
represented evidence source
institution
Endocrine journal
represented evidence source
institution
BMC endocrine disorders
represented evidence source
institution
Clinical pharmacokinetics
represented evidence source
Claim: Not linked · Evidence: 2f748d42b788b3ef04182c86c85d9618
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Claim: Not linked · Evidence: 3b48a93b8be3f8727c0de88e6db09975
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Claim: Not linked · Evidence: a4b0cf9a132eed02d27970f61dca9ccd
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Claim: Not linked · Evidence: 84af84e4773dd681932d60859e4b0175
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Claim: Not linked · Evidence: e4b3dfd3889eff9ff4ed5ccc8f54d747
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Claim: Not linked · Evidence: 7fcc7b8155a8aa069c0c34dda4862d0a
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
Claim: Not linked · Evidence: 5556e83bcc2d0071e02f12bdcdc2a959
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
Claim: Not linked · Evidence: 1c423557e9fe8579ecc954adf02ff08f
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.
Claim: Not linked · Evidence: 5486670fd11ba086985c568ce5c3c93d
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
Claim: Not linked · Evidence: d01aa264ec956be6a81ee332490f61a0
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.
Generated: 9/18/2026, 3:04:02 PM
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
Structure source
Generated from this record's governed amino-acid sequence
Identifier
Not applicable — not a database structure
Method
Schematic layout ordered by residue position only; not a molecular-dynamics, homology, or fold prediction
Confidence / limitations
Illustrative only. Not physically accurate; carries no structural, binding-site, or activity meaning.
Provenance
WPF governed PeptideChemistry record
Retrieved / last reviewed
2026-09-17
This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.
Loading interactive preview…
Durable source IDs
6/6
Claim-to-source chain
Partial
Evidence searched through: Not recorded
Last accountable review: Not recorded
Inspect unresolved signals (4)
No governed reviewed scientific source is represented.
The last accountable evidence-review date is not recorded.
At least one claim-to-original-source traceability step is not represented.
The literature search-through date is not recorded.
These are documentary and scientific-review signals, not conclusions of harm, ineffectiveness, safety, or absence of research.
Human relevance0
Study design0
Evidence breadth0
Consistency0
Governance quality0
Uncertainty resolution0
Why this rating
No governed reviewed scientific evidence is available.
Source-level review states (6)
identifiedother
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
This maturity index describes evidence-base development and governance. It is not a probability of efficacy, safety, truth, medical advice, or regulatory approval. Read the methodology.